This review provides a brief description of the main structural and functional features of the κ opioid receptor, along with the properties of its agonists and the potential for using these in medicine. Of all the opioid receptor subtypes, κ receptors are the most attractive in terms of creating new drugs with a minimum of side effects. The opioid κ receptor is a member of the superfamily of metabotropic G-protein-coupled receptors. Opioid κ receptors are widely distributed in the CNS and at the periphery. They are involved in numerous physiological processes, including analgesia, regulation of neuroendocrine secretion, water balance, drinking and feeding behavior, autonomic functions, and the mechanisms of learning and memory. Data have been reported on the existence of three subtypes of κopioid receptor, though the molecular properties of only subtype 1 (ê1) have been studied.
Similar content being viewed by others
References
J. V. Aldrich and P. J. McLaughlin, AAPS J., 2, 312 – 322 (2009).
M. R. Bruchas and C. Chavkin, J. Psychopharm., 2, 137 – 147 (2010).
G. W. Pasternak, “The Opiate receptors,“ in: The Receptors (2011), p. 516.
A. M. Trescot, S. Datta, M. Lee, et al., Pain Physician., 11, 133 – 153 (2008).
K. M. Wannemachera, A. Terskiy, S. Bian, et al., Brain Res., 3 – 26 (2008).
T. Kenakin, Trends Pharmacol. Sci., 28(8), 407 – 415 (2007).
M. J. Marinissen and J. S. Gutkind, Trends Pharmacol. Sci., 22(7), 368 – 376 (2001).
B. E. Kane, B. Svensson, and D. M. Ferguson, AAPS J., 1, 126 – 137 (2006).
L. Y. Liu-Chen, Life Sci., 75(5), 511 – 536 (2004).
A. W. Bruijnzeel, Brain Res. Rev., 1, 127 – 146 (2009).
J. P. McLaughlin, M. Xu, K. Mackie, et al., J. Biol. Chem., 278(36), 34631 – 34640 (2003).
W. J. Carlezon, C. Beguin, A. T. Knoll, et al., J. Pharmacol. Ther., 3, 334 – 343 (2009).
A. C. Gray, I. M. Coupar, and P. J. White, Life Sci., 7, 674 – 685 (2006).
X. Y. Li, L. Sun, J. He, et al., Brain Res., 1326, 30 – 39 (2010).
B. A. S. Reyes, C. Chavkin, and E. J. Bockstaele, J. Comp. Neurol., 512(3), 419 – 431 (2009).
A. I. Obara, I. R. Parkitna, M. Korostynski, et al., Pain., 141(3), 283 – 291 (2009).
Y. H. Wang, J. F. Sun, Y. M. Tao, et al., Acta Pharmacol. Sin., 31(9), 1065 – 1070 (2010).
J. C. Lemos and C. Chavkin, “Kappa-opioid receptor function,“ in: Opiate Receptors, Pasternak G. W. (ed.) (2011), pp. 226 – 305.
P. Rivière, Br. J. Pharmacol., 141(8), 1331 – 1334 (2004).
C. Stein and L. J. Lang, Cur. Opin. Pharmacol., 9(1), 3 – 8 (2009).
N. Q. Phan, T. Lotts, A. Antal, et al., Acta Derm. Venereol., 92(5), 555 – 560 (2012).
O. Pol, J. R. Palacio, and M. M. Puig, J. Pharmacol. Exp. Ther., 306(2), 455 – 462 (2003).
M. Ohsawa and J. Kamei, J. Pharmacol. Sci., 98(1), 25 – 32 (2005).
K. K. Rau, R. M. Caudle, B. Y. Cooper, et al., J. Chem. Neuroanat., 29(4), 255 – 264 (2005).
B. Kivell and T. E. Prisinzano, Psychopharm., 210(2), 109 – 119 (2010).
Y. M. Tao, Q. L. Li, and C. F. Zhang, Eur. J. Pharmacol., 584(2 – 3), 306 – 311 (2008).
P. K. Peterson, G. Gekker, J. R. Lokensgard, et al., Biochem. Pharmacol., 61(9), 1145 – 1151 (2001).
S. Hu, W. S. Sheng, and R. B. Rock., J. Neuroimmune Pharmacol., 6(4), 528 – 539 (2011).
D. E. Rusovici, S. S. Negus, N. K. Mello, et al., Eur. J. Pharmacol., 485(1), 119 – 125 (2004).
E. R. Butelman and M. J. Kreek, Res. Devel. Opioid-Related Ligands, 13, 245 – 256 (2013).
M. K. Greenwald and M. L. Stitzer, Drug Alcohol. Depend., 53(1), 17 – 30 (1998).
J. C. Gillis, P. Benfield, and K. L. Goa, Drugs, 50(1), 157 – 175 (1995).
S. P. Jaw, M. Makimura, B. Hoskins, et al., Eur. J. Pharmacol., 239(1 – 3), 133 – 140 (1993).
W. R. Martin, Pharmacol. Rev., 19(4), 463 – 521 (1967).
P. Gharagozlou, E. Hashemi, T. M. DeLorey, et al., BMC Pharmacol., 6, 3 (2006).
G. W. Pasternak and Y. Pan, Pharmacol. Rev., 65, 1257 – 1317 (2013).
J. M. Bidlack, D. J. Cohen, J. P. McLaughlin, et al., J. Pharmacol. Exp. Ther., 302(1), 374 – 380 (2002).
K. M. Kumor, C. A. Haertzen, R. E. Johnson, et al., J. Pharmacol. Exp. Ther., 238(3), 960 – 968 (1986).
J. Dortch-Carnes and D. E. Potter, CNS Drug Rev., 11(2), 195 – 212 (2005).
A. Coop and A. D. MacKerell, Am. J. Pharm. Educ., 66(2), 153 – 156 (2002).
S. Archer, S. D. Glick, and J. M. Bidlack, Neurochem. Res., 21(11), 1369 – 1373 (1996).
T. E. Prisinzano, K. Tidgewell, and W. W. Harding, AAPS J., 7(3), 592 – 599 (2005).
J. Szmuszkovicz, Part II: 1991 – 1998. Progress in Drug Research., 53, 1 – 51 (1991).
P. F. Von Voigtlander and R. A. Lewis, Progress in Neuropsychopharmacol. Biol. Psych., 6(4 – 6), 467 – 470 (1982).
J. Kamei, Pulmonary Pharmacol., 9(5 – 6), 349 – 355 (1996).
M. Hiramatsu and T. Kameyama, Methods Findings Experim. Clin. Pharmacol., 20(7), 595 – 599 (1998).
H. Nagase and H. Fujii, Top. Cur. Chem., 299, 29 – 62 (2011).
L. Zhou, K. M. Lovell, K. J. Frankowski, et al., J. Biol. Chem., 288(51), 36703 – 36716 (2013).
P. F. Von Voigtlander and R. A. Lewis, J. Pharmacol. Exp. Ther., 246(1), 259 – 262 (1988).
S. G. Holtzman, Pharmacol. Biochem. Behav., 66(3), 517 – 522 (2000).
R. S. Zukin, M. Eghbali, D. Olive, et al., Proc. Natl. Acad. Sci. USA, 85(11), 4061 – 4065 (1988).
C. P. France, F. Medzihradsky, and J. H. Woods, J. Pharmacol. Exp. Therap., 268(1), 47 – 58 (1994).
V. Kumar,M. A. Marella, L. Cortes-Burgos, et al., Bioorg. Med. Chem. Let., 10(22), 2567 – 2570 (2000).
A. S. Yekkirala, J. Postdoctoral. Res., 4, 9 – 23 (2013).
A. La Regina, P. Petrillo, M. Sbacchi, et al., Life Sci., 42(3), 293 – 301 (1988).
W. Binder., H. Machelska, S. Mousa, et al., Anesth., 94(6), 1034 – 1044 (2001).
P. M. Wall and C. Messier, Brain Res., 856(1 – 2), 259 – 280 (2000).
M. J. Millan, A. Czonkowski, A. Lipkowskiet, et al., J. Pharmacol. Exp. Therap., 251(1), 342 – 350 (1989).
R. W. Gear, O. Bogen, L. F. Ferrari, et al., Neuroscience, 257, 139 – 148 (2014).
T. H. Privette and D. M. Terrian, Psychopharmacol., 118(4), 444 – 450 (1995).
C. D. Soulard, S. Guerif, A. Payne, et al., J. Pharmacol. Exp. Ther., 279(3), 1379 – 1385 (1996).
M. L. Wadenberg, CNS Drug. Rev., 9(2), 187 – 201 (2003).
M. Kunihara, M. Ohyama, M. Nakano, et al., Life Sci., 45, No. 13, 1191 – 1198 (1989).
Z. Stachura and Z. S. Herman, Pol. J. Pharmacol., 46(1 – 2), 37 – 41 (1994).
M. K. Pugsley, E. J. Yu, and A. L. Goldin, Gen. Pharmacol., 34(6), 417 – 427 (2000).
J. McDonald and D. G. Lambert, Anaesthesia Intensive Care Med., 11, 505 – 509 (2013).
C. R. McLaughlin, Q. Tao, and M. E. Abood, Drug Alcohol Depend., 38, 261 – 269 (1995).
A. Barber and R. Gottschlich, Expert Opin. Investig. Drugs, 6(10), 1351 – 1368 (1997).
S. L. Walsh, E. C. Strain, M. E. Abreu, et al., Psychopharmacol., 157(2), 151 – 162 (2001).
P. R. Halfpenny, D. S. Horwell, J. Hughes, et al., J. Med. Chem., 33(1), 286 – 291 (1989).
J. C. Hunter, G. E. Leighton, K. G. Meecham, et al., Br. J. Pharmacol., 101(1), 183 – 189.
G. E. Leighton, M. A. Johnson, and K. G. Meecham, Br. J. Pharmacol., 72(3), 915 – 922 (1987).
F. C. Tortella, Opioids: Epilepsy Neuroprotection, 104(2), 343 – 360 (1993).
K. B. Mackay, K. Kusumoto, D. I. Graham, et al., Brain Res., 618(2), 213 – 219 (1993).
R. Dawkins, M. E. Lebsack, S. Wright, et al., J. Clin. Pharmacol., 31, 864 (1991).
P. A. Reece, A. J. Sedman, S. Rose, et al., J. Clin. Pharmacol., 34(11), 1126 – 1132 (1994).
G. F. Costello, R. James, and J. S. Shaw, J. Med. Chem., 34(1), 181 (1991).
J. J. Barlow, T. P. Blackburn, and G. F Costello, J. Med. Chem., 34(11), 3149 – 3158 (1991).
M. Narita, C. Kaneko, K. Miyoshi, et al., Neuropsychopharmacol., 31(4), 739 – 750 (2006).
J. S. Shaw, J. A. Carroll, P. Alcock, et al., Br. J. Pharmacol., 96(4), 986 – 992 (1989).
H. Kepta, V. Kayser, and G. Guilbaud, Eur. J. Pharmacol., 277(2 – 3), 275 (1995).
A. Barber, G. D. Bartoszyk, H. M. Bender, et al., Br. J. Pharmacol., 113(4), 1317 – 1327 (1994).
N. L. Caram-Salas, G. Reyes-Garcna, G. D. Bartoszyk, et al., Eur. J. Pharmacol., 573(1 – 3), 75 – 83 (2007).
V. Vecchietti, A. Giordani, and G. Giardina, J. Med. Chem., 34(1), 397 – 403 (1991).
E. Zeynalov, M. Nemoto, P. D. Hurn, et al., J. Cereb. Blood. Flow. Metab., 26(3), 414 – 420 (2006).
S. Fang, H. Xu, J Lu, Y. Zhu, et al., Neurochem Res., 38(11), 2305 – 2312 (2013).
T. Y. Chen, T. Goyagi, T. J. Toung, et al., Stroke. J. Cerebral Circ., 35(5), 1180 – 1185 (2004).
A. Naylor, D. B. Judd, J. E. Lloyd, et al., J. Med. Chem., 36(15), 2075 – 2083 (1993).
B. S. Meldrum, Brain Pathol., 3(4), 405 – 412 (1993).
B. S. Meldrum, Neurology, 44(11), Supplement 8, 14 – 23 (1994).
P. J. Birch, H. Rogers, and A. G. Hayes, Br. J. Pharmacol., 103(3), 1819 – 1823 (1991).
A. I. Faden and S. Salzman, Trends Pharmacol. Sci., 13(1), 29 – 35, (1992).
J. F. Herrero and P. M. Headley, Br. J. Pharmacol., 110(1), 303 – 309 (1993).
J. Ho, A. J. Mannes, R. Dubner, and R. M. Caudle, J. Pharmacol. Exp. Ther., 281(1), 136 – 141 (1997).
M. C. Ko and S. M. Husbands, J. Pharmacol. Exp. Ther., 328(1), 193 – 200 (2009).
J. J. Wagner, R. M. Caudle, and C. Chavkin, J. Neurosci., 12(1), 132 – 141 (1992).
R. M. Caudle, C. Chavkin, and R. Dubner, J. Neurosci., 14(9), 5580 – 5589 (1994).
Y. Tsukahara-Ohsumi, F. Tsuji, M. Niwa, et al., Eur. J. Pharmacol., 647(1 – 3), 62 – 67 (2010).
Y. Tsukahara-Ohsumi, F. Tsuji, M. Niwa, et al., Eur. J. Pharmacol., 671(1 – 3), 53 – 60 (2011).
H. Nagase, J. Hayakawa, K. Kawamura, et al., Chem. Pharm. Bul., 46(2), 66 – 369 (1998).
H. Kumagai, T. Ebata, K. Takamori, et al., Am. J. Nephrol., 36(2), 175 – 183 (2012).
B. Wikstrtsm, R. Gellert, S. D. Ladefoged, et al., J. Am. Soc. Nephrol., 16(12), 3742 – 3747 (2005).
K. Nakao, K. Ikeda, T. Kurokawa, et al., Nihon Shinkei Seishin Yakurigaku Zasshi., 28(2), 75 – 85 (2008).
T. Endoh, H. Matsuura, A. Tajima, et al., Life Sci., 65(16), 1685 – 1694 (1999).
T. Endoh, A. Tajima, T. Suzuki, et al., Eur. J. Pharmacol., 387(2), 133 – 140 (2000).
H. Kumagai, T. Ebata, K. Takamori, et al., Nephrol. Dial. Transplant., 25(4), 1251 – 1257 (2010).
H. Kumagai, K. Yamamoto, T. Kushiyama, et al., Kidney Dialysis, 70(4), 651 – 657 (2011).
S. Inui, Y. Shirakawa, and S. Itami, J. Dermatol., 39(10), 1253 (2011).
H. Ichinose, Eur. J. Pharmacol., 606(1 – 3), 102 – 108 (2009).
K. Yamamizu, S. Furuta, S. Katayama, et al., Blood., 118(3), 775 – 785 (2011).
Thomson Reuters Integrity: Official search site for the “Thomson Reuters Integrity“ system [electronic resource]. URL: http://integrity.thomson-pharma.com (accessed on April 22, 2011).
M. Delvaux and J. Frexinos, Expert. Opin. Investig. Drugs, 10(1), 97 – 110 (2001).
F. De Ponti, Front Pharmacol., 4, 7 (2013).
M. J. Callahan, J. Clin. Gastroenterol., 35(1), 58 – 67 (2002).
B. Le Bourdonnec, C. W. Ajello, P. R. Seida, et al., Bioorg. Med. Chem. Let., 15(10), 2647 – 2652 (2005).
J. C. Eisenach, R. Carpenter, and R. Curry, Pain., 101(1 – 2), 89 – 95 (2003).
M. Camilleri, Neurogastroenterol. Motil., 20(9), 971 – 979 (2008).
A. W. Mangel and G. A. Hicks, Clin. Exp. Gastroenterol., 5, 1 – 10 (2012).
N. J. Talley, R. S. Choung, M. Camilleri, et al., Aliment. Pharmacol., 27(11), 1122 – 1131 (2008).
A. W. Mangel and V. S. Williams, Expert Opin. Investig. Drugs, 19(10), 1257 – 1264 (2010).
G. X. Xie, F. Meng F, A. Mansour, et al., Proc. Natl. Acad. Sci. USA,, 91, 3779 – 3783 (1994).
A. T. Knoll and J. Carlezon, Brain Res., 1314, 56 – 73 (2010).
M. Connor and I. Kitchen, Br. J. Pharmacol., 147(4), 349 – 350 (2006).
T. Oshima, J. Pharmacol. Sci., 98(1), 25(2005).
Author information
Authors and Affiliations
Additional information
Translated from Khimiko-Farmatsevticheskii Zhurnal, Vol. 50, No. 1, pp. 3-11 – 10, January, 2016.
Rights and permissions
About this article
Cite this article
Grechko, O.Y., Spasov, A.A. & Shtareva, D.M. Opioid κ Receptors as a Molecular Target for the Creation of a New Generation of Analgesic Drugs. Pharm Chem J 50, 1–9 (2016). https://doi.org/10.1007/s11094-016-1388-z
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11094-016-1388-z